Loading...

Bio-Gene Technology Limited

BGT.AXASX
Healthcare
Biotechnology
A$0.02
A$0.00(0.00%)

Bio-Gene Technology Limited (BGT.AX) Stock Competitors & Peer Comparison

See (BGT.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
BGT.AXA$0.02+0.00%6.4M-2.10-A$0.01N/A
CSL.AXA$216.60-4.16%104.9B22.56A$9.60+1.96%
TLX.AXA$18.33+1.27%6.2B458.25A$0.04N/A
MSB.AXA$2.38+0.42%3B-12.53-A$0.19N/A
NEU.AXA$17.17-0.92%2.1B15.75A$1.09N/A
CU6.AXA$3.39-4.24%1.3B-21.19-A$0.16N/A
PYC.AXA$1.30-1.52%758.2M-11.82-A$0.11N/A
OPT.AXA$0.60+0.00%738.8M-1.40-A$0.43N/A
CUV.AXA$12.93+7.84%648.1M16.79A$0.77+0.39%
IMM.AXA$0.26+4.08%374.3M-8.50-A$0.03N/A
Showing 1 to 10 of 57 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

BGT.AX vs CSL.AX Comparison August 2025

BGT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGT.AX stands at 6.4M. In comparison, CSL.AX has a market cap of 104.9B. Regarding current trading prices, BGT.AX is priced at A$0.02, while CSL.AX trades at A$216.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGT.AX currently has a P/E ratio of -2.10, whereas CSL.AX's P/E ratio is 22.56. In terms of profitability, BGT.AX's ROE is -1.15%, compared to CSL.AX's ROE of +0.17%. Regarding short-term risk, BGT.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BGT.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;